Last €1.22 EUR
Change Today -0.006 / -0.49%
Volume 0.0
PJ2 On Other Exchanges
Symbol
Exchange
OTC US
Toronto
Frankfurt
As of 9:33 AM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

prometic life sciences inc (PJ2) Snapshot

Open
€1.22
Previous Close
€1.23
Day High
€1.22
Day Low
€1.22
52 Week High
09/22/14 - €1.25
52 Week Low
09/25/13 - €0.51
Market Cap
649.1M
Average Volume 10 Days
743.7
EPS TTM
--
Shares Outstanding
530.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROMETIC LIFE SCIENCES INC (PJ2)

Related News

No related news articles were found.

prometic life sciences inc (PJ2) Related Businessweek News

No Related Businessweek News Found

prometic life sciences inc (PJ2) Details

ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparation, plasma-derived therapeutics, and small-molecule drugs. The company also offers its technologies for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutics products targeting unmet medical needs in the fields of fibrosis, anemia, cancer, and autoimmune disease, as well as plasma-derived therapeutics in orphan drug indications. It operates in two segments, Therapeutics and Protein Technology. The Therapeutics segment’s lead product includes PBI-4050, which targets unmet medical needs, such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. This segment also develops PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases; and PBI-1402, a drug candidate for the treatment of anemia indications. The Protein Technology segment provides plasma protein purification system, a solution for the extraction and purification of therapeutic proteins from human plasma; bioseparation products based on applications of its patented Mimetic Ligand technology for various biopharmaceutical companies; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

Founded in 1992

prometic life sciences inc (PJ2) Top Compensated Officers

Chief Executive Officer, President and Non-In...
Total Annual Compensation: C$435.0K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: C$322.3K
Chief Executive Officer of ProMetic BioScienc...
Total Annual Compensation: C$238.5K
General Counsel and Corporate Secretary
Total Annual Compensation: C$197.0K
Senior Vice President of Product & Asia Pacif...
Total Annual Compensation: C$283.6K
Compensation as of Fiscal Year 2013.

prometic life sciences inc (PJ2) Key Developments

ProMetic Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

ProMetic Life Sciences Inc. reported earnings results for the second quarter and six months ended June 30, 2014. The company total revenues for the second quarter ended June 30, 2014 were CAD 4.4 million compared to CAD 5.2 million for the second quarter ended June 30, 2013 representing a decrease of CAD 0.8 million. The company generated a net profit of CAD 23.4 million for the quarter ended June 30, 2014 compared to a net loss of CAD 2.5 million for the quarter ended June 30, 2013. The net profit generated is mainly due to the recognition of a gain on revaluation of the equity investment of CAD 24.3 million representing the difference between the fair value and the carrying amount of company's equity interest in NantPro just before the transaction. The company total revenues for the six months ended June 30, 2014 were CAD 10.1 million compared to CAD 9.6 million during the comparative 2013 period, an increase of CAD 0.5 million.

ProMetic Life Sciences Inc. Announces Management Changes

ProMetic Life Sciences Inc. announced the promotion of Mr. Bruce Pritchard to the newly created position of chief operating officer as well as the nomination of Mr. Stefan Clulow to its board of directors, both effective as of August 12, 2014. Mr. Pritchard will, in the interim, continue to assume his chief financial officer duties until his replacement is duly appointed. Mr. Clulow is filling the board vacancy following the retirement of Mr. Robert Lacroix from company's board of directors. Mr. Pritchard is currently a member of the Governing Council of The Institute of Chartered Accountants of Scotland, a member of the Board of Examiners of The Institute of Directors and is a non-executive director of both Imanova Limited and Being Digital Limited.

ProMetic Life Sciences Inc. to Report Q2, 2014 Results on Aug 14, 2014

ProMetic Life Sciences Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 14, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PJ2:GR €1.22 EUR -0.006

PJ2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PJ2.
View Industry Companies
 

Industry Analysis

PJ2

Industry Average

Valuation PJ2 Industry Range
No financial data is available for PJ2.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROMETIC LIFE SCIENCES INC, please visit www.prometic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.